Register / Login

We're evolving!

The website is currently being upgraded to include our new suite of offerings. Check back at the end of the month for a breakdown of our new services!

Questions? Contact us at:

office@md-education.com

3rd Annual

AML-ALL

EU Focus Meeting

Updating Knowledge & Clinical Practice in 2024

St. Ermin’s Hotel, London, UK

Friday 25 October 2024 - Saturday 26 October 2024

Presentations will be available online for 12 months

Meeting content distributed to 12,000+ HCPs

For more information get in touch!

=

Co-chair

Charlie Craddock, MD

Queen Elizabeth Hospital, Birmingham

=

Co-chair

Naval Daver, MD

MD Anderson Cancer Center, Houston, Texas

=

Co-chair

Cristina Papayannidis, MD

Austin Diagnostic Clinic, TX

=

Co-chair

Elias Jabbour, MD

MD Anderson Cancer Center, Houston, Texas

Dear Colleagues and Friends,

We are delighted to extend our warmest invitation to the multinational congress AML-ALL EU Focus 2024, to be held at St. Ermin’s Hotel, London, UK on 25 October 2024.

This congress provides pivotal collaboration aimed at advancing AML-ALL research and patient treatment.

This congress presents an opportunity for medical professionals to engage in the exchange of knowledge, expertise, and insights, as well as networking with leading experts from around the world.

Engage in riveting presentations, participate in thought-provoking debates, round-table discussions, and connect with peers at informal social gatherings.

All congress content will be accessible online for a full year, reaching an extensive audience of healthcare professionals worldwide.

People stood in a circle, smiling, with a cup of water

Agenda & Faculty

AML-ALL EU Focus Meeting, Friday 25 October 2024 - Saturday 26 October 2024

07:00

Registration Opens

07:45

Opening remarks – Ryan Fitzpatrick, CEO, MD Education

Session 1: TBD

08:00

Research and progress in AML

=

Hagop Kantarjian, MD

MD Anderson Cancer Center, Houston, Texas

08:20

Practical approach to incorporating genomics in treatment decision making in Fit adult AML

=

Paresh Vyas, MD

University of Oxford, UK

08:40

Incorporating MRD into treatment decision making in newly diagnosed AML, focus on NPM1 and FLT3 mutated AML

=

Christoph Röllig, MD

University Hospital Carl Gustav Carus, Dresden, Germany

09:00

Current Status and Updates in the Diagnosis, Prognosis and Management of Secondary and Therapy Related AML

=

Priyanka Mehta, MD

University Hospital Bristol NHS Foundation Trust, UK

09:20

Optimising transplant outcomes in high-risk AML?

=

Charlie Craddock, MD

Queen Elizabeth Hospital, Birmingham

09:40

Panel Discussion

10:00

Coffee Break

Session 2: TBD

10:20

Biology of Ph pos ALL: new insights for a risk stratification?

=

Ilaria Iacobucci, MD

St. Jude Children’s Research Hospital, US

10:40

How I treat Ph positive ALL in 2024: US

=

Elias Jabbour, MD

MD Anderson Cancer Center, Houston, Texas

11:00

How I treat Ph positive ALL in 2024: Europe

=

Robin Foà, MD

University of Rome, Italy

11:20

SCT in Ph+ ALL: is it still necessary?

=

Emmanuelle Clappier, MD

Hôpital Saint-Louis, France

11:40

Open Issues in Pediatric ALL

=

Rob Pieters, MD

Princess Máxima Center, Utrecht, Netherlands

12:00

Panel Discussion

12:20

Lunch Break, Networking & Group Photo

13:10

Industry Supported Independent Expert Discussion

Session 3: TBD

13:55

Which patients with newly diagnosed AML should receive a venetoclax based regimen in 2024

=

Naval Daver, MD

MD Anderson Cancer Center, Houston, Texas

14:15

Novel approaches to treatment of TP53m and other high-risk AML

=

Rami Komrokji, MD

Moffitt Cancer Center, Florida

14:35

Menin inhibitors in the management of AML

=

Emma Searle, MD

The Christie NHS Foundation Trust, Manchester, UK

14:55

Immunotherapeutic strategies in AML

=

Marion Subklewe, MD

University Hospital of Munich, Germany

15:15

Managament of disease relapse in fit and unfit AML patients

=

Alessandro Isidori, MD

Marche Nord Hospital, Pesaro, Italy

15:35

Panel Discussion

15:55

Coffee Break & Networking

Session 4: TBD

16:15

SCT in Adult Ph Neg ALL: How, When and for Which Patients?

=

Anna Castleton, MD

The Christie NHS Foundation Trust, Manchester, UK

16:35

CAR-T cells in ALL: progress and pitfalls

=

Marion Subklewe, MD

University Hospital of Munich, Germany

16:55

Debate: R/R Ph neg ALL: CAR-T cells or antibodies?

=

CAR-T Cells

Claire Roddie, MD

University College London, UK

=

Antibodies

Nicolas Boissel, MD

Assistance Publique – Hôpitaux de Paris, France

17:15

Panel & Debate Discussion

17:45

Adjourn